Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.

Published on May 8, 2021in European Urology Oncology
· DOI :10.1016/J.EUO.2021.04.005
Elizabeth A. Green , Elizabeth Green3
Estimated H-index: 3
+ 5 AuthorsAshish M. Kamat76
Estimated H-index: 76
(University of Texas MD Anderson Cancer Center)
Sources
Abstract
Abstract Context Bladder and kidney cancers require invasive procedures for definitive diagnosis, and bladder cancer requires repeated procedures to monitor for disease recurrence. Given the recent work to identify molecular alterations in liquid biopsies to diagnose and monitor these diseases, a synthesis of the growing body of evidence is merited. Objective To review current data on cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) and to synthesize their roles in the diagnosis, monitoring, and prognostication of bladder and kidney cancer. Evidence acquisition A literature review was conducted through August 15, 2020 including prospective and retrospective studies. Keywords included “cell-free DNA”, “circulating tumor DNA”, “kidney cancer”, “renal cell carcinoma”, “bladder cancer”, “upper tract urothelial carcinoma”, and “urothelial carcinoma”. Evidence synthesis Urine tumor DNA (utDNA) has sensitivity of 91% and specificity of 96% for detecting bladder cancer, outperforming cystoscopy and cytology. Increased utDNA and ctDNA are associated with progression from non–muscle-invasive to muscle-invasive disease. In patients undergoing cystectomy, ctDNA detection is associated with worse overall survival and disease recurrence, and with persistent tumor on surgical pathology in those who received neoadjuvant chemotherapy. cfDNA is significantly higher in patients with kidney cancer than in healthy controls or in those with benign lesions, and detectable ctDNA and increased cfDNA are associated with decreased survival. Conclusions Combined data from small studies provide evidence that cfDNA and ctDNA may have the ability to detect, monitor, and prognosticate in patients with bladder, upper tract urothelial, and kidney cancers. Patient summary In this review, we looked at the work that has been published so far on cell-free and circulating tumor DNA in bladder and kidney cancers. We found that while many of the studies were small, there is evidence that cell-free tumor DNA can emerge as a tool for the diagnosis and monitoring of treatment response for patients with these cancers.
📖 Papers frequently viewed together
49 Citations
References65
Newest
#1Heather J. Chalfin (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 10
#2Stephanie Glavaris (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 10
Last. David J. McConkey (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 19
view all 12 authors...
Abstract Despite considerable advances in the management of urothelial carcinoma (UC), better risk stratification and enhanced detection of minimal residual disease are still urgent priorities to prolong survival while avoiding the morbidity of overtreatment. Circulating tumor cells and DNA (CTCs, ctDNA) are two biologically distinct “liquid biopsies” that may potentially address this need, although they have been understudied in UC to date and their relative utility is unknown. To this end, mat...
9 CitationsSource
#1Kendal Jensen (UW: University of Washington)H-Index: 1
#2Eric Q. Konnick (UW: University of Washington)H-Index: 15
Last. Colin C. Pritchard (UW: University of Washington)H-Index: 51
view all 12 authors...
Importance Cell-free DNA (cfDNA) testing is increasingly used in the treatment of patients with advanced prostate cancer. Clonal hematopoiesis of indeterminate potential (CHIP) can interfere with cfDNA testing and cause incorrect interpretation of results. There is an urgent need to better understand this problem following recent US Food and Drug Administration approval of poly(ADP) ribose polymerase inhibitors (PARPi) for metastatic prostate cancer based on variants in DNA repair genes that can...
5 CitationsSource
#1Petros Grivas (UW: University of Washington)H-Index: 22
#2Aly-Khan A. Lalani (McMaster University)H-Index: 12
Last. Guru Sonpavde (Harvard University)H-Index: 60
view all 17 authors...
Abstract Cell-free circulating DNA (cfDNA) can be used for noninvasive profiling of tumor genomic aberrations. We hypothesized that molecular alterations may inform prognostication in advanced urothelial carcinoma (aUC). We evaluated 124 aUC patients who underwent cfDNA analysis using a 73-gene sequencing panel (Guardant360). The association of molecular alterations and clinical factors with overall survival (OS) and failure-free-survival (FFS) was evaluated using the Kaplan-Meier method and Cox...
12 CitationsSource
#1Miguel Alcaide (SFU: Simon Fraser University)H-Index: 27
#2Matthew C. Cheung (SFU: Simon Fraser University)H-Index: 15
Last. Ryan D. Morin (SFU: Simon Fraser University)H-Index: 53
view all 11 authors...
Cell-free DNA (cfDNA) has become a comprehensive biomarker in the fields of non-invasive cancer detection and monitoring, organ transplantation, prenatal genetic testing and pathogen detection. While cfDNA samples can be obtained using a broad variety of approaches, there is an urgent need to standardize analytical tools aimed at assessing its basic properties. Typical methods to determine the yield and fragment size distribution of cfDNA samples are usually either blind to genomic DNA contamina...
8 CitationsSource
#1Pier Vitale Nuzzo (UniGe: University of Genoa)H-Index: 13
#2Jacob E. Berchuck (Harvard University)H-Index: 8
Last. Matthew L. Freedman (Broad Institute)H-Index: 71
view all 26 authors...
Improving early cancer detection has the potential to substantially reduce cancer-related mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP–seq) is a highly sensitive assay capable of detecting early-stage tumors. We report accurate classification of patients across all stages of renal cell carcinoma (RCC) in plasma (area under the receiver operating characteristic (AUROC) curve of 0.99) and demonstrate the validity of this assay to identify patients...
23 CitationsSource
#1Sumanta K. Pal (City of Hope National Medical Center)H-Index: 60
#2Dean F. Bajorin (Cornell University)H-Index: 96
Last. Jonathan E. Rosenberg (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 60
view all 18 authors...
BACKGROUND: Infigratinib (BGJ398) is a potent and selective fibroblast grown factor receptor 1 to 3 (FGFR1-3) inhibitor with significant activity in patients with advanced or metastatic urothelial carcinoma bearing FGFR3 alterations. Given the distinct biologic characteristics of upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB), the authors examined whether infigratinib had varying activity in these settings. METHODS: Eligible patients had metastatic urotheli...
17 CitationsSource
#1Asaf Zviran (Cornell University)H-Index: 9
#2Rafael C. Schulman (Cornell University)H-Index: 5
Last. Dan A. Landau (Cornell University)H-Index: 24
view all 42 authors...
In many areas of oncology, we lack sensitive tools to track low-burden disease. Although cell-free DNA (cfDNA) shows promise in detecting cancer mutations, we found that the combination of low tumor fraction (TF) and limited number of DNA fragments restricts low-disease-burden monitoring through the prevailing deep targeted sequencing paradigm. We reasoned that breadth may supplant depth of sequencing to overcome the barrier of cfDNA abundance. Whole-genome sequencing (WGS) of cfDNA allowed ultr...
18 CitationsSource
#1Kathryn Lasseter (Brigham and Women's Hospital)H-Index: 3
#2Amin Nassar (Harvard University)H-Index: 10
Last. David J. Kwiatkowski (Brigham and Women's Hospital)H-Index: 142
view all 16 authors...
Plasma cell-free DNA (cfDNA) variant analysis is commonly used in many cancer subtypes. Cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) has shown high sensitivity for cancer detection. To date, studies have not compared the sensitivity of both methods in a single cancer subtype. cfDNA from 40 metastatic RCC (mRCC) patients was subjected to targeted panel variant analysis. For 34 of 40, cfMeDIP-seq was also performed. A separate cohort of 38 mRCC patients were used in cfMeDI...
7 CitationsSource
#1Jack V. W. Bacon (UBC: University of British Columbia)H-Index: 5
#2Matti Annala (UTA: University of Tampere)H-Index: 25
Last. Lucia Nappi (UBC: University of British Columbia)H-Index: 13
view all 12 authors...
Abstract Purpose There is a lack of molecularly-informed biomarkers for patients with metastatic renal cell carcinoma (RCC). Plasma cell-free DNA (cfDNA) sequencing is a minimally-invasive alternative to tissue for profiling the genome in other cancers but relevance in metastatic RCC remains unclear. Materials and Methods Whole blood was collected from 55 metastatic RCC patients. Plasma cfDNA and leukocyte DNA were subjected to targeted sequencing across 981 cancer genes. Matched tumour tissue f...
6 CitationsSource
#1Marko Babjuk (Charles University in Prague)H-Index: 31
#2Maximilian Burger (University of Regensburg)H-Index: 53
Last. Viktor Soukup (First Faculty of Medicine, Charles University in Prague)H-Index: 16
view all 18 authors...
Abstract Context This overview presents the updated European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS). Objective To provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations. Evidence acquisition A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines has been performed annually since the last published version in 201...
287 CitationsSource
Cited By0
Newest